



Contents lists available at ScienceDirect

# Vaccine

journal homepage: [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)

## Letter to the Editor

### Letter to Editor



#### To the Editor:

The article by Wilkins and Snape (<https://doi.org/10.1016/j.vaccine.2017.07.056>) includes brief summaries of current recommendations for the use of vaccines against group B meningococcal disease. The recommendations pertaining to each vaccine in the US are described differently, as a result of which it may be wrongly inferred that their respective recommendation status differs. To avoid confusion we would like to make clear that in the US the recommendations of the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (ACIP) are applicable to both available vaccines 4CMenB (Bexsero) and rLP2086 (Trumenba). This includes both the Category A recommendation for individuals aged  $\geq 10$  years at increased risk of disease, and the Category B recommendation for individuals aged 16–23 years [1–3].

Philip Watson & Leonard Friedland, GSK

### Conflict of interest

All authors declare they are employed by the GSK group of companies and hold shares in the GSK group of companies.

### References

- [1] Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged  $\geq 10$  years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015. *MMWR Morb Mortal Wkly Rep* 2015;64:608–12.
- [2] MacNeil JR, Lorry Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015. *MMWR Morb Mortal Wkly Rep* 2015;64:1171–6.
- [3] Patton ME, Stephens D, Moore K, MacNeil JR. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine—advisory committee on immunization practices, 2016. *MMWR Morb Mortal Wkly Rep* 2017;66:509–13.

Philip S. Watson

Leonard R. Friedland

GSK, 5 Crescent Drive, Philadelphia, PA 19112, USA

E-mail address: [philip.s.watson@gsk.com](mailto:philip.s.watson@gsk.com) (P.S. Watson).

Available online 27 October 2017